含嘧啶环的 d-葡萄糖共轭硫脲类化合物作为 2 型糖尿病中 α-淀粉酶、α-葡萄糖苷酶、DDP-4 和 PTP1B 的多靶点抑制剂的设计、合成、抑制活性和分子模拟研究。

IF 3.597 Q2 Pharmacology, Toxicology and Pharmaceutics
MedChemComm Pub Date : 2024-06-28 DOI:10.1039/D4MD00334A
Vu Ngoc Toan, Do Son Hai, Hoang Thi Kim Van, Nguyen Minh Tri, Duong Ngoc Toan, Nguyen Thi Thanh Mai and Nguyen Dinh Thanh
{"title":"含嘧啶环的 d-葡萄糖共轭硫脲类化合物作为 2 型糖尿病中 α-淀粉酶、α-葡萄糖苷酶、DDP-4 和 PTP1B 的多靶点抑制剂的设计、合成、抑制活性和分子模拟研究。","authors":"Vu Ngoc Toan, Do Son Hai, Hoang Thi Kim Van, Nguyen Minh Tri, Duong Ngoc Toan, Nguyen Thi Thanh Mai and Nguyen Dinh Thanh","doi":"10.1039/D4MD00334A","DOIUrl":null,"url":null,"abstract":"<p >A series of tetra-<em>O</em>-acetyl-α-<small>D</small>-glucopyranosyl thioureas <strong>8a–l</strong> of substituted 2-aminopyrimidines <strong>4a–l</strong> have been designed and synthesized. The latter were prepared from corresponding chalcones <strong>3a–l</strong> of <em>p</em>-bromoacetophenone and appropriate substituted benzaldehydes by their reaction with guanidine. The target thiourea compounds <strong>8a–l</strong> exhibited significant inhibitory activity <em>in vitro</em> against enzymes that were related to type 2 diabetes mellitus, including α-amylase, α-glucosidase, DPP-4, and PTP1B. Amongst these thioureas, compound <strong>8k</strong> with an <em>ortho</em>-methoxy group was the most potential enzyme inhibitor against α-amylase with an IC<small><sub>50</sub></small> value of 9.72 ± 0.34 μM. Its <em>meta</em>-isomer <strong>8j</strong> was the strongest inhibitor against α-glucosidase with IC<small><sub>50</sub></small> = 9.73 ± 0.72 μM. In the inhibition against DPP-4, compound <strong>8f</strong> with a <em>para</em>-bromo substituent exhibited the strongest activity with an IC<small><sub>50</sub></small> value of 2.53 ± 0.03 nM. In the inhibition against PTP1B, compound <strong>8h</strong> with a <em>para</em>-isopropyl substituent had the strongest inhibitory activity with an IC<small><sub>50</sub></small> value of 2.74 ± 0.03 μM. The enzyme kinetics of the most active compounds, including <strong>8j</strong>, <strong>8f</strong> and <strong>8h</strong> against α-glucosidase, DPP-4, and PTP1B, respectively, were studied. The obtained results showed that <strong>8j</strong> was a competitive α-glucosidase inhibitor with an inhibitory constant <em>K</em><small><sub>I</sub></small> value of 9.31 μM. Compound <strong>8f</strong> was a non-competitive inhibitor for DDP-4 with an inhibitory constant <em>K</em><small><sub>I</sub></small> value of 12.57 μM. Compound <strong>8h</strong> was also a non-competitive inhibitor for DDP-4 with an inhibitory constant <em>K</em><small><sub>I</sub></small> value of 12.41 μM. The cytotoxicity of the most active compounds, including <strong>8f</strong> and <strong>8k</strong> (against α-amylase), <strong>8i</strong> and <strong>8j</strong> (against α-glucosidase), <strong>8a</strong>, <strong>8f</strong>, and <strong>8g</strong> (against DPP-4), and <strong>8d</strong>, <strong>8f</strong>, and <strong>8h</strong> (against PTP1B) was screened. The obtained cytotoxicity showed that all tested inhibitors were noncytotoxic to human normal cell line 3T3. Induced fit docking simulations of all synthesized compounds <strong>8a–l</strong> were performed on four enzymes 4W93 (for α-amylase), 3TOP (for α-glucosidase), 3W2T (for DPP-4), and 1NNY (for PTP1B). Key interactions of each of these ligands with residues in the active pocket of each studied enzyme have been shown.</p>","PeriodicalId":88,"journal":{"name":"MedChemComm","volume":" 10","pages":" 3395-3417"},"PeriodicalIF":3.5970,"publicationDate":"2024-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Design, synthesis, inhibitory activity, and molecular simulations study for d-glucose-conjugated thioureas containing pyrimidine ring as multitarget inhibitors against α-amylase, α-glucosidase, DDP-4, and PTP1B in Type 2 diabetes mellitus†\",\"authors\":\"Vu Ngoc Toan, Do Son Hai, Hoang Thi Kim Van, Nguyen Minh Tri, Duong Ngoc Toan, Nguyen Thi Thanh Mai and Nguyen Dinh Thanh\",\"doi\":\"10.1039/D4MD00334A\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p >A series of tetra-<em>O</em>-acetyl-α-<small>D</small>-glucopyranosyl thioureas <strong>8a–l</strong> of substituted 2-aminopyrimidines <strong>4a–l</strong> have been designed and synthesized. The latter were prepared from corresponding chalcones <strong>3a–l</strong> of <em>p</em>-bromoacetophenone and appropriate substituted benzaldehydes by their reaction with guanidine. The target thiourea compounds <strong>8a–l</strong> exhibited significant inhibitory activity <em>in vitro</em> against enzymes that were related to type 2 diabetes mellitus, including α-amylase, α-glucosidase, DPP-4, and PTP1B. Amongst these thioureas, compound <strong>8k</strong> with an <em>ortho</em>-methoxy group was the most potential enzyme inhibitor against α-amylase with an IC<small><sub>50</sub></small> value of 9.72 ± 0.34 μM. Its <em>meta</em>-isomer <strong>8j</strong> was the strongest inhibitor against α-glucosidase with IC<small><sub>50</sub></small> = 9.73 ± 0.72 μM. In the inhibition against DPP-4, compound <strong>8f</strong> with a <em>para</em>-bromo substituent exhibited the strongest activity with an IC<small><sub>50</sub></small> value of 2.53 ± 0.03 nM. In the inhibition against PTP1B, compound <strong>8h</strong> with a <em>para</em>-isopropyl substituent had the strongest inhibitory activity with an IC<small><sub>50</sub></small> value of 2.74 ± 0.03 μM. The enzyme kinetics of the most active compounds, including <strong>8j</strong>, <strong>8f</strong> and <strong>8h</strong> against α-glucosidase, DPP-4, and PTP1B, respectively, were studied. The obtained results showed that <strong>8j</strong> was a competitive α-glucosidase inhibitor with an inhibitory constant <em>K</em><small><sub>I</sub></small> value of 9.31 μM. Compound <strong>8f</strong> was a non-competitive inhibitor for DDP-4 with an inhibitory constant <em>K</em><small><sub>I</sub></small> value of 12.57 μM. Compound <strong>8h</strong> was also a non-competitive inhibitor for DDP-4 with an inhibitory constant <em>K</em><small><sub>I</sub></small> value of 12.41 μM. The cytotoxicity of the most active compounds, including <strong>8f</strong> and <strong>8k</strong> (against α-amylase), <strong>8i</strong> and <strong>8j</strong> (against α-glucosidase), <strong>8a</strong>, <strong>8f</strong>, and <strong>8g</strong> (against DPP-4), and <strong>8d</strong>, <strong>8f</strong>, and <strong>8h</strong> (against PTP1B) was screened. The obtained cytotoxicity showed that all tested inhibitors were noncytotoxic to human normal cell line 3T3. Induced fit docking simulations of all synthesized compounds <strong>8a–l</strong> were performed on four enzymes 4W93 (for α-amylase), 3TOP (for α-glucosidase), 3W2T (for DPP-4), and 1NNY (for PTP1B). Key interactions of each of these ligands with residues in the active pocket of each studied enzyme have been shown.</p>\",\"PeriodicalId\":88,\"journal\":{\"name\":\"MedChemComm\",\"volume\":\" 10\",\"pages\":\" 3395-3417\"},\"PeriodicalIF\":3.5970,\"publicationDate\":\"2024-06-28\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"MedChemComm\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://pubs.rsc.org/en/content/articlelanding/2024/md/d4md00334a\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"Pharmacology, Toxicology and Pharmaceutics\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"MedChemComm","FirstCategoryId":"1085","ListUrlMain":"https://pubs.rsc.org/en/content/articlelanding/2024/md/d4md00334a","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
引用次数: 0

摘要

我们设计并合成了一系列取代 2-氨基嘧啶 4a-l 的四-O-乙酰基-α-d-吡喃葡萄糖基硫脲类化合物 8a-l。后者是由对溴苯乙酮的相应查耳酮 3a-l 和适当的取代苯甲醛与胍反应制备的。目标硫脲化合物 8a-l 在体外对与 2 型糖尿病有关的酶(包括 α-淀粉酶、α-葡萄糖苷酶、DPP-4 和 PTP1B)具有显著的抑制活性。在这些硫脲类化合物中,带有正交甲氧基的化合物 8k 是对α-淀粉酶最有潜力的酶抑制剂,其 IC50 值为 9.72 ± 0.34 μM。它的元异构体 8j 是对α-葡萄糖苷酶最强的抑制剂,IC50 = 9.73 ± 0.72 μM。在对 DPP-4 的抑制作用中,具有对溴取代基的化合物 8f 的活性最强,其 IC50 值为 2.53 ± 0.03 nM。在对 PTP1B 的抑制作用中,具有对位异丙基取代基的化合物 8h 具有最强的抑制活性,其 IC50 值为 2.74 ± 0.03 μM。研究了最有效化合物(包括 8j、8f 和 8h)分别对 α-葡萄糖苷酶、DPP-4 和 PTP1B 的酶动力学。结果表明,8j 是一种竞争性的 α-葡萄糖苷酶抑制剂,其抑制常数 K I 值为 9.31 μM。化合物 8f 对 DDP-4 是一种非竞争性抑制剂,其抑制常数 K I 值为 12.57 μM。化合物 8h 对 DDP-4 也是一种非竞争性抑制剂,其抑制常数 K I 值为 12.41 μM。筛选了最有活性化合物的细胞毒性,包括 8f 和 8k(针对 α-淀粉酶)、8i 和 8j(针对 α-葡萄糖苷酶)、8a、8f 和 8g(针对 DPP-4)以及 8d、8f 和 8h(针对 PTP1B)。细胞毒性结果表明,所有测试的抑制剂对人类正常细胞株 3T3 均无细胞毒性。对 4W93(针对 α-淀粉酶)、3TOP(针对 α-葡萄糖苷酶)、3W2T(针对 DPP-4)和 1NNY(针对 PTP1B)四种酶进行了所有合成化合物 8a-l 的诱导拟合对接模拟。这些配体与所研究的每种酶的活性袋中的残基之间的关键相互作用都已显示出来。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Design, synthesis, inhibitory activity, and molecular simulations study for d-glucose-conjugated thioureas containing pyrimidine ring as multitarget inhibitors against α-amylase, α-glucosidase, DDP-4, and PTP1B in Type 2 diabetes mellitus†

Design, synthesis, inhibitory activity, and molecular simulations study for d-glucose-conjugated thioureas containing pyrimidine ring as multitarget inhibitors against α-amylase, α-glucosidase, DDP-4, and PTP1B in Type 2 diabetes mellitus†

Design, synthesis, inhibitory activity, and molecular simulations study for d-glucose-conjugated thioureas containing pyrimidine ring as multitarget inhibitors against α-amylase, α-glucosidase, DDP-4, and PTP1B in Type 2 diabetes mellitus†

A series of tetra-O-acetyl-α-D-glucopyranosyl thioureas 8a–l of substituted 2-aminopyrimidines 4a–l have been designed and synthesized. The latter were prepared from corresponding chalcones 3a–l of p-bromoacetophenone and appropriate substituted benzaldehydes by their reaction with guanidine. The target thiourea compounds 8a–l exhibited significant inhibitory activity in vitro against enzymes that were related to type 2 diabetes mellitus, including α-amylase, α-glucosidase, DPP-4, and PTP1B. Amongst these thioureas, compound 8k with an ortho-methoxy group was the most potential enzyme inhibitor against α-amylase with an IC50 value of 9.72 ± 0.34 μM. Its meta-isomer 8j was the strongest inhibitor against α-glucosidase with IC50 = 9.73 ± 0.72 μM. In the inhibition against DPP-4, compound 8f with a para-bromo substituent exhibited the strongest activity with an IC50 value of 2.53 ± 0.03 nM. In the inhibition against PTP1B, compound 8h with a para-isopropyl substituent had the strongest inhibitory activity with an IC50 value of 2.74 ± 0.03 μM. The enzyme kinetics of the most active compounds, including 8j, 8f and 8h against α-glucosidase, DPP-4, and PTP1B, respectively, were studied. The obtained results showed that 8j was a competitive α-glucosidase inhibitor with an inhibitory constant KI value of 9.31 μM. Compound 8f was a non-competitive inhibitor for DDP-4 with an inhibitory constant KI value of 12.57 μM. Compound 8h was also a non-competitive inhibitor for DDP-4 with an inhibitory constant KI value of 12.41 μM. The cytotoxicity of the most active compounds, including 8f and 8k (against α-amylase), 8i and 8j (against α-glucosidase), 8a, 8f, and 8g (against DPP-4), and 8d, 8f, and 8h (against PTP1B) was screened. The obtained cytotoxicity showed that all tested inhibitors were noncytotoxic to human normal cell line 3T3. Induced fit docking simulations of all synthesized compounds 8a–l were performed on four enzymes 4W93 (for α-amylase), 3TOP (for α-glucosidase), 3W2T (for DPP-4), and 1NNY (for PTP1B). Key interactions of each of these ligands with residues in the active pocket of each studied enzyme have been shown.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
MedChemComm
MedChemComm BIOCHEMISTRY & MOLECULAR BIOLOGY-CHEMISTRY, MEDICINAL
CiteScore
4.70
自引率
0.00%
发文量
0
审稿时长
2.2 months
期刊介绍: Research and review articles in medicinal chemistry and related drug discovery science; the official journal of the European Federation for Medicinal Chemistry. In 2020, MedChemComm will change its name to RSC Medicinal Chemistry. Issue 12, 2019 will be the last issue as MedChemComm.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信